Wave Crashes Down On Duchenne Fail
Suvodirsen Terminated After Negative Trial
Executive Summary
Having spectacularly failed even to match Sarepta’s Exondys 51 in the restoration of dystrophin in Duchenne muscular dystrophy patients, Wave's future is dependent on soon-to-be published data on a Huntington’s disease therapy.